Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Kiniksa Pharmaceuticals International, plc
KNSA
NASDAQ·Healthcare·Medical - Pharmaceuticals·Mkt cap $4.7B
$63.43
▲ +0.87%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$26.27 - $64.81
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 129.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Specialized focus on rare inflammatory diseases with limited competition
- Proprietary monoclonal antibody technology platform
- Experienced management team with deep pharma expertise
- ARCALYST market approval and revenue generation
Bear Case
2 risks
- Low volatility (beta 0.1).
- Growth premium of 1.7x vs sector peers. Elevated but may be justified by growth trajectory.
Growth
Strong growth ahead
ARCALYST market expansion and label extensions
Value
Growth premium of 1.7x vs sector peers. Elevated but may be justified by growth trajectory.
Momentum
Hot
+28.8% over 3m
Quality
Strong
High-growth business (57% revenue growth, 55% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying KNSA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Jul 28, 2026
Earnings recap unavailable for this period.
EPS surprise · last 4Q
Q1 26
$0.30
Q4 25
$0.19
Q3 25
$0.25
Q2 25
$0.24
Next: Jul 28, 2026
Revenue trend · last 8Q
—
—
—
—
+44%
+61%
+65%
+56%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$108.6M
$112.2M
$122.5M
$137.8M
$156.8M
$180.9M
$202.1M
$214.3M
Margins · last 8Q
Gross
55.0%
Operating
13.7%
Profit
10.5%
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$65.00
▲ +2.5% vs $63.43
Latest: Wedbush · $72.00 · Jun 29, 2026
2 analysts covering
vs Industry
How KNSA stacks vs Medical - Pharmaceuticals
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related
Peers & themes
Peers
No peer data available.
Themes
No themes assigned.